---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-002534"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2023-02-13T23:59:59+00:00"
generated_at: "2026-06-19T16:02:59.085904+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Corbus licenses Nectin-4 ADC CRB-701 from CSPC, announces 1-for-30 reverse stock split

## Summary
- Exclusive license for CRB-701 (Nectin-4 ADC) from CSPC; upfront $7.5M, up to $685M in milestones/royalties.
- CRB-701 is clinical-stage with FDA IND clearance; Phase 1 in China; US trial planned 2024.
- Reverse stock split 1:30 effective Feb 14, 2023 to regain Nasdaq $1.00 bid price compliance.
- Corbus maintains cash runway through Q2 2024, per CEO Yuval Cohen.
- Territory includes US, Canada, EU, UK, Australia; CSPC retains rest of world.

## SEC filing metadata
- accession: 0000950170-23-002534
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2023-02-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 5.03, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000095017023002534/0000950170-23-002534-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000095017023002534/crbp-20230209.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-002534
- JSON: https://secwatch.observer/filing/0000950170-23-002534.json
- Plain text: https://secwatch.observer/filing/0000950170-23-002534.txt

## Key facts
- Governance Changes
  Corbus Pharmaceuticals Holdings, Inc.: Amendment to Certificate of Incorporation to effect a 1-for-30 reverse stock split (effective 2023-02-14).
  - Change: charter amendment
  - Effective: 2023-02-14
  source text: On February 9, 2023, the Board approved a 1-for-30 Reverse Stock Split (“Reverse Stock Split”) and the Company filed the Amendment for the Reverse Stock Split with the Secretary of State of the State of Delaware. The Reverse Stock Split will become effective in accordance with the terms of the Amendment at 12:01 AM Eastern Time on February 14, 2023 (the “Effective Time”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595097/000095017023002534/0000950170-23-002534-index.htm
- Material Agreements
  Corbus Pharmaceuticals Holdings, Inc. entered into Exclusive License Agreement with CSPC Megalith Biopharmaceutical Co., Ltd. valued at $7.5 million (effective 2023-02-12).
  - Action: entry
  - Agreement: license
  - Counterparty: CSPC Megalith Biopharmaceutical Co., Ltd.
  - Value: $7.5 million
  - Effective: 2023-02-12
  source text: On February 12, 2023, Corbus Pharmaceuticals Holdings, Inc. (the “Company”) entered into an Exclusive License Agreement (the “License Agreement”) with CSPC Megalith Biopharmaceutical Co., Ltd. (“CSPC”), pursuant to which the Company received an exclusive license to obtain certain exclusive rights to develop and commercialize CRB-701 (SYS6002), a novel clinical stage antibody drug conjugate targeting Nectin-4.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595097/000095017023002534/0000950170-23-002534-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.